Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial

The aim of this study was to determine the dose-limiting toxicity (DLT) and establish the recommended dose for mitomycin C added every 3 weeks to the standard combination dose of capecitabine. Cohorts of at least three patients with pretreated gastrointestinal carcinoma received capecitabine 1000 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofheinz, R-D, Hartmann, J T, Willer, A, Oechsle, K, Hartung, G, Gnad, U, Saussele, S, Kreil, S, Bokemeyer, C, Hehlmann, R, Hochhaus, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409860/
https://www.ncbi.nlm.nih.gov/pubmed/15238990
http://dx.doi.org/10.1038/sj.bjc.6602025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409860/
https://www.ncbi.nlm.nih.gov/pubmed/15238990
http://dx.doi.org/10.1038/sj.bjc.6602025

Ejemplares similares